The ESMO presentation everyone’s been waiting for

Plus, new data on the combination of Amgen’s Imdelltra and Astrazeneca’s Imfinzi in extensive-stage small cell lung cancer Adobe Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from the major European cancer conference in your inbox. Hello again from Madrid, where we can tell you it’s Day 2 of the European Society for Medical Oncology’s annual meeting, but definitely not what day of the week it is.

Perhaps some of the other nearly 40,000 people here can relate? Enjoy today’s newsletter; we’ll be back with one more edition wrapping up the conference Monday afternoon. And on Thursday, join us for The STAT Recap , where we’ll catch you up on all the ESMO news you need to know, and answer your questions live.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account?

Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54.